根据美国证券交易委员会(SEC)最新披露的文件,Mira Pharma(股票代码:MIRA)宣布其候选药物Ketamir-2在一期临床试验中未观察到具有临床显著性的解离或致精神病副作用。
该试验结果标志着Ketamir-2在安全性方面取得重要进展,为其后续临床开发铺平道路。公司强调,这一发现有望推动该药物在治疗领域的进一步探索。
根据美国证券交易委员会(SEC)最新披露的文件,Mira Pharma(股票代码:MIRA)宣布其候选药物Ketamir-2在一期临床试验中未观察到具有临床显著性的解离或致精神病副作用。
该试验结果标志着Ketamir-2在安全性方面取得重要进展,为其后续临床开发铺平道路。公司强调,这一发现有望推动该药物在治疗领域的进一步探索。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.